News and Announcements
YPB’s New Tracer Production Line Operational
- Published October 06, 2015 3:35PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th October 2015, ASX Announcement
Highlights
- YPB’s new production line for invisible tracer operational
- 400% increase in captivity to produce YPB’s invisible tracer
- First batch produced on new production line
- YPB tracer included in 20 million fapiaos (tax invoices/receipts) to date – contract for 48 million per year 2015-2017
- First run of 300,00 bank deposit certificates complete in national bank trial – targeting only one county thus far
Ant-counterfeiting technology company YPB Group Limited (ASX:YPB) has commenced use of a new production line for its invisible tracer ant-counterfeit material. The first successful production run comes after recent investment into its development in China.
Rapid growth in demand for YPB’s invisible tracer made it necessary to extend the production capacity.
After three months building the new production line, YPB will have the ability to increase production by up to 400%, providing adequate support for YPB’s growing activity across China, USA, Australia and Thailand.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
